PRESS RELEASE: GlaxoSmithKline appoints Andrew Witty CEO designate

GlaxoSmithKline appoints Andrew Witty CEO designate

Issued: 8 October 2007, London, 7am

The Board of GlaxoSmithKline plc (“GSK”) (LSE & NYSE: GSK) today announced the appointment of Andrew Witty as CEO Designate, GlaxoSmithKline.

Andrew Witty, currently President, Pharmaceuticals Europe for GlaxoSmithKline, will succeed Dr Jean-Pierre Garnier following his retirement as Chief Executive Officer at the end of May 2008.

Sir Christopher Gent, Chairman, GlaxoSmithKline said: “Andrew’s appointment follows a rigorous selection process by the Board of Directors. The fact that we have been able to select a successor to JP from three strong internal candidates is a testament to the quality of management at GSK. The Board is confident that Andrew will build on JP’s considerable achievements which have positioned GSK as a leader of the pharmaceutical industry.”

JP Garnier said: “Andrew has made many significant contributions to GSK and I am very pleased that he is to be our next CEO. I look forward to working with him during our handover and wish him every success.”

GlaxoSmithKline — one of the world’s leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.